Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julian Rydzek

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Blood|November 2, 2017
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7<sup>+</sup> normal lymphocytesTea Gogishvili, Sophia Danhof, Sabrina Prommersberger, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 22, 2018
Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell PlatformJulian Rydzek, Thomas Nerreter, Haiyong Peng, et al.
Science Translational Medicine|July 5, 2019
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cellsKatrin Mestermann, Theodoros Giavridis, Justus Weber, et al.
Leukemia|February 24, 2018
CAR T-cells targeting FLT3 have potent activity against FLT3<sup>-</sup>ITD<sup>+</sup> AML and act synergistically with the FLT3-inhibitor crenolanibHardikkumar Jetani, Irene Garcia-Cadenas, Thomas Nerreter, et al.
Nature Immunology|July 8, 2020
Inefficient CAR-proximal signaling blunts antigen sensitivityVenugopal Gudipati, Julian Rydzek, Iago Doel-Perez, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Blood|November 2, 2017
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7<sup>+</sup> normal lymphocytesTea Gogishvili, Sophia Danhof, Sabrina Prommersberger, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 22, 2018
Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell PlatformJulian Rydzek, Thomas Nerreter, Haiyong Peng, et al.
Science Translational Medicine|July 5, 2019
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cellsKatrin Mestermann, Theodoros Giavridis, Justus Weber, et al.
Leukemia|February 24, 2018
CAR T-cells targeting FLT3 have potent activity against FLT3<sup>-</sup>ITD<sup>+</sup> AML and act synergistically with the FLT3-inhibitor crenolanibHardikkumar Jetani, Irene Garcia-Cadenas, Thomas Nerreter, et al.
Nature Immunology|July 8, 2020
Inefficient CAR-proximal signaling blunts antigen sensitivityVenugopal Gudipati, Julian Rydzek, Iago Doel-Perez, et al.
Pageof 1